Leadership
Dr Paresh Kishorbhai Dadhaniya, the founder and MD of Plexus PreClinical Services, is a leading technical person with over twenty-six years of experience in biomedical research.
An avid learner, Dr Paresh ensures he’s updated with recent advances by attending and contributing to relevant conferences and being a lifetime member of the leading Toxicology and Animal Scientist Societies. His publications are regularly published on well-known platforms, and the community admires his knowledge and calibre.
Industry Experience
Dr Paresh started his professional journey with Jai Research Foundation (JRF) (one of the oldest OECD GLP certified CRO in India) as a Veterinary Officer. He worked at grass root level to understand & implement best animal care practices for highest quality animal supplies and also actively involved in implementation of GLP quality system at the JRF.
As his extended journey of experience, in his association with Cadila Pharmaceuticals Limited (one of the privately held pharmaceuticals company in India) supported the company on designing of laboratory animal breeding facility and GLP test facility. Also, implemented GLP quality system and obtained GLP certification. He also led the innovation team to deliver the projects from NCE synthesis till clinical phase investigation.
During his association with RCC, Hyderabad he led animal breeding and as additional responsibility Quality Assurance team and executed key role in implementation of GLP quality system and subsequent certification.
In Baxter, he developed and led the team for the safety assessment of medical devices, container closer systems, parenteral pharmaceuticals products and deliver the projects well before timeline.
Dr Paresh’s invaluable contributions to drug development undoubtedly make him a veteran in his domain and proved his calibre. Here are some of his notable contributions:
● He has worked in various industries (i.e., CROs, Pharmaceuticals, biotechnology medical device) as an in charge of basic research, safety studies, risk assessment and animal breeding.
● Lead the innovation team responsible for NCE development from chemical synthesis till IND submission and approval for appropriate clinical phase.
● He has played a crucial role at various levels of decision making including as TFM in setting up 3 test facilities from inception till GLP certification.
● Developed and managed toxicological risk assessment teams for pharmaceutical and medical device industries.
● He has successfully handled Swiss GLP audits from FOPH, Switzerland as Head - QA at RCC laboratories.
● At RCC laboratories he has undertaken intensive training and actively involved in designing and developing SPF animal breeding facilities
in collaboration with Harlan.
● He is experienced in managing and successfully completing globally collaborative projects in various therapeutic areas.
● He has worked for NCE development and IND fillings (3 nos), which were successfully approved for phase1
● Evaluated toxicology of over 72 products inclusive of small molecules, vaccines, biosimilars, polyherbal, medical devices, cosmetics…
● Actively involved in designing and developing new laboratory animal houses from their inception.
● He has proved his excellence in scientific fraternity by designing the studies (POCs), their execution, communicating with regulators and replying the response to regulatory queries.
● He played a key role as mentor by coaching and training of community in various organizations.
 |
Business development: Jay Soni
Jay Soni is a highly accomplished Business Development professional with a proven track record in the dynamic realms of both clinical and preclinical research. With a focus on preclinical projects, Jay leverages his extensive experience to foster strategic client relationships and drive impactful results.
His Education is
B. Sc. in Microbiology from Gujarat University
M. Sc. in Cancer Biology from Gujarat University
Currently located in Toronto, Canada, Jay possesses a global perspective and brings a wealth of academic knowledge to his business development endeavors. His educational background in Microbiology and Cancer Biology from Gujarat University serves as a strong foundation for navigating the complexities of the life sciences industry.
Throughout his illustrious career, Jay has consistently demonstrated a keen ability to excel through effective collaboration and a client-centric approach. His robust interpersonal skills, combined with an unwavering commitment to excellence, enable him to navigate the intricacies of preclinical and clinical research successfully. Jay takes pride in being a proactive contributor to organizational success, consistently striving to optimize client satisfaction through tailored solutions and insightful engagement.
Possessing a comprehensive understanding of the preclinical research landscape, Jay brings a unique blend of expertise to the business development arena. His pivotal role as a Research and Development professional at GCRI from 2013 to 2015, with a focus on Cell Biology, showcases his deep knowledge and hands-on experience in the preclinical domain. Subsequently, he spearheaded preclinical business development at Cadila Pharmaceuticals from 2016 to 2018, achieving significant milestones and further enhancing his expertise.
In his role as a proposals developer from 2018 to 2023 across various companies, Jay has successfully secured more than 50 projects, underscoring his ability to forge valuable partnerships. These achievements have solidified Jay's reputation as a trustworthy professional capable of driving growth and success in any dynamic business development role within the preclinical research sectors. His emphasis on client orientation and a results-driven approach positions him as a valuable asset in advancing partnerships and achieving organizational objectives. Currently located in Toronto, Jay brings a global perspective to his strategic business development initiatives.
 |
Dr. Nilesh Patel, a scientific advisor to PPS, has been passionate Pharmacologist by training, having more than 17 years of research experience. His niche area of research is immunopharmacology, metabolic and inflammatory condition. He has been supervised 44 M.Pharm and 8 PhD dissertation theses so far. He has +80 international & national publications (research findings and review articles) and conference proceedings to his credit. Several dozens of Government and industry sponsored research projects worth more than 2.5 crore have been accomplished so far. He has been board and advisory member (Independent Non-Executive) to 03 Pvt Ltd companies in India. In addition, Ministry of Fisheries, Animal Husbandry and Dairying, Government of India, New Delhi nominated as CPCSEA nominee to couples of pharmaceutical industries, CRO, medical and pharmacy institutes to monitor and control animal experimentation on laboratory animals. He has awarded several scientific prizes (09) for best research paper.
Dr. Nilesh started his professional journey with S.K. Patel College of Pharmaceutical Education & Research, Ganpat University (second oldest private pharmacy institute in Gujarat state) as an Assistant Professor. He started working at grass root level to begin industry sponsored projects (first time in academic across state). From 2008, he has begun catering small scale industries for safety, efficacy and pharmacokinetic studies as per regulatory compliances to synthetic drugs, polyherbal formulations and medical devices companies and they have succeeded to achieve regulatory (DCGI) approvals eventually. He sets very high bar amongst academic fraternity apart from core teaching responsibilities. During his professorship, he kept motivating master graduates for translational research. It is reflected by patent, best poster awards and publication in peer reviewed journals.
He has been entrepreneur after 15 years of teaching and academic research experience and recently ventured preclinical stage biopharmaceutical start up, is focusing primarily on development of a novel class of biologics to selectively interact and activate targeted T cells directly within the body to transform the treatment of cancer, infectious diseases, autoimmune diseases. During this journey, he has done clinical (from patient) in-vitro T cell modulation studies (activation, expansion and exhaustion assays using flow cytometry), immunomodulation assays. He has nailed down his skills in development and evaluation of drugs on 3D spheroids. Besides, he has been dynamic in stem cells research too.